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Detection of Human Papillomavirus DNA in
Cutaneous Squamous Cell Carcinoma among
Immunocompetent Individuals
Maryam M. Asgari1,2, Nancy B. Kiviat3, Cathy W. Critchlow4, Joshua E. Stern3, Zsolt B. Argenyi2,3,
Gregory J. Raugi2, Daniel Berg2, Peter B. Odland2, Stephen E. Hawes4 and Ethel-Michele de Villiers5
The presence of certain types of human papillomavirus (HPV) is a known risk factor for the development of
anogenital squamous cell carcinomas (SCCs). A similar association has been hypothesized for cutaneous SCCs,
although, to our knowledge, no studies to date have combined sensitive HPV DNA detection techniques with
epidemiologic data controlling for known risk factors to explore the association. We designed a case–control
study examining HPV prevalence using highly sensitive PCR-detection assays in tissue samples from 85
immunocompetent patients with histologically confirmed SCCs and 95 age-matched individuals without a prior
history of skin cancer. A standardized interview was administered to all study subjects to collect information
pertaining to potential confounding variables. The overall detection rate of HPV DNA was high in case lesions
(54%) and perilesions (50%) and in both sun-exposed normal tissue (59%) and non-sun-exposed normal tissue
(49%) from controls. In comparing case tissue to control tissue, there was no differential detection of HPV DNA
across various HPV species. However, HPV DNA from b-papillomavirus species 2 was more likely to be
identified in tumors than in adjacent healthy tissue among cases (paired analysis, odds ratio¼ 4.0, confidence
interval¼ 1.3–12.0). The high prevalence of HPV DNA detected among controls suggests that HPV DNA is widely
distributed among the general population. However, the differential detection of HPV b-papillomavirus species
in tumors among cases suggests that certain HPV types may be involved in the progression of cutaneous SCCs.
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INTRODUCTION
Cutaneous squamous cell carcinoma (SCC) is the second
most common cancer among Caucasians worldwide (Preston
and Stern, 1992), with an age-adjusted incidence of 100–150
per 100,000 per year (Gray et al., 1997). The known risk
factors for cutaneous SCC include exposure to UV light, fair
complexion, older age, male sex, smoking, chronic skin
ulcers and burn scars, immunosuppression, as well as
exposure to certain chemical carcinogens (Alam and Ratner,
2001; Foote et al., 2001). Human papillomavirus (HPV) has
been postulated to be an additional risk factor for cutaneous
SCC development (Kiviat, 1999; Biliris et al., 2000).
HPVs are common viruses that infect epithelial cells, with
108 different types identified to date (de Villiers et al., 2004).
HPVs are classified into higher order ‘‘genera’’ (alpha, beta,
and gamma contain the majority of cutaneous HPVs) and
lower order ‘‘species’’ (Figure 1). Although it is now widely
accepted that certain high-risk HPV types (mainly
a-papillomaviruses) play a central role in cervical and
anogenital cancers (zur Hausen, 1996; Nobbenhuis et al.,
1999; Walboomers et al., 1999), the role of HPV in the
development of cutaneous SCCs remains controversial. There
is strong evidence implicating HPV in the pathogenesis of
cutaneous SCCs in immunosuppressed individuals. Persons
afflicted with epidermodysplasia verruciformis, an inherited
disorder of cell-mediated immunity, are unable to adequately
control infection with specific HPVs and develop large
numbers of flat, atypical warts, 40–60% of which can
eventually undergo malignant transformation (Majewski and
Jablonska, 1997). Solid organ transplant recipients also
develop large numbers of warts, primarily on sun-exposed
skin, that carry a high risk of subsequent malignant
transformation to cutaneous SCCs (Purdie et al., 1993;
Harwood et al., 2000). HPV DNA is detected in high levels
within cutaneous SCCs (up to 80%) that arise in solid organ
transplant recipients (Tieben et al., 1994; Berkhout et al.,
1995; Shamanin et al., 1996; de Villiers et al., 1997).
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The mechanism by which HPV causes oncogenesis in
cutaneous SCC development is unclear. The genomes of
mucosal HPV types (a-papillomaviruses) containing E6 and
E7 genes can replicate as extrachromosomal episomes
separate from host DNA and potentially act through specific
molecular changes in the E6 and E7 pathways that impair
tumor suppressor genes such as p53 and Rb. HPV integration
into the host genome may also cause disruption of genomic
stability and facilitate further progression toward cell
transformation. Alternatively, the low-risk HPV types
(b- and g-papillomaviruses) seem to require the presence of
additional mutagens, such as UV radiation, to induce
proliferation of infected keratinocytes. The latter may acquire
mutations in tumor suppressor genes or oncogenes through
other mutagens, such as UV radiation, and develop into
tumors. A better understanding of the role of HPV in skin
cancer arising in immunocompetent hosts can come from
probing both tumor (lesion) and clinically adjacent normal
skin (perilesion) for DNA, which previously studies have
failed to do.
Among immunocompetent subjects, several studies have
reported variable detection rates of HPV in cutaneous SCCs
ranging from 27 to 70% (Shamanin et al., 1996; Harwood
et al., 2000, 2004; Iftner et al., 2003). The variability in HPV
detection rates is likely technique dependent. Different PCR
consensus primers have variable sensitivity for HPV types and
some fail to recognize novel HPV types. An additional
weakness in most published case–control studies is that they
fail to capture epidemiologic data and adjust for potential
confounding risk factors for skin cancer, such as sun exposure
history, propensity to sunburn, exposure to chemical
carcinogens, and previous history of skin cancer.
This study examines the role of HPV in cutaneous SCCs
among immunocompetent subjects. Unlike previous studies
that failed to use primers capable of detecting a wide range of
cutaneous HPVs, we used three distinct sets of both
consensus and degenerate primers to obtain maximum
sensitivity for the detection of all HPV types. In addition,
we collected detailed information on potential confounding
variables such as skin type, history of sun exposure, and
exposure to mutagens. We compared HPV detection rates
within cases, looking at SCCs (lesion) as well as clinically
uninvolved adjacent skin (perilesion) to examine the role of
HPV in tumor progression. The strength in this study design is
that it allows for the perilesional tissue to serve as the
‘‘internal control.’’ For comparison as an ‘‘external control,’’
we selected age-matched individuals with no self-reported
history of skin cancer. We obtained two biopsies from each
control subject, one from a sun-exposed and one from a sun-
protected site, to study the effects of UV exposure on HPV
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Figure 1. Phylogenetic tree containing genus a-, b-, and c-papillomaviruses. The outer circle encompasses genera, the inner circle the species, and the
numbers at the ends of the branches identify type. C-numbers refer to candidate HPV types. The four numbers associated with the arrows show the total number
of HPV-positive DNA samples detected in lesion, perilesion, sun-exposed and sun-protected tissues, respectively. (These numbers take into account
multiple infections with the same species in a given subject and, therefore, may differ from those listed in Table 2.) (Figure is modified from a previously
published version by De Villiers et al. (2004), with copyright permission granted by Elsevier.)
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prevalence. By designing the study such that there is an
internal control and external control for each tumor, by
ascertaining self-reported epidemiologic variables that influ-
ence skin cancer risk, and by using highly sensitive HPV
primers, we aim to rigorously explore the role of HPV in
cutaneous SCCs and to distinguish our research from
previously published findings.
RESULTS
A total of 227 immunocompetent Caucasian individuals (132
cases and 95 controls) had skin biopsies for HPV detection
assays. Of the 132 SCC cases, only 85 had confirmed SCCs
upon histologic examination of the surgically excised speci-
men. The remaining 47 cases did not have histologically
confirmed SCCs at the time of surgical treatment of their
tumors and were therefore excluded from the analysis. The
pathologic classification of the 85 histologically confirmed
SCC cases are as follows: 52 (61%) were invasive SCCs, 3
(4%) were borderline invasive SCCs, and 30 (35%) were SCC
in situ. With regard to anatomic location of the tumors, 64
(75%) arose on the head/neck, 7 (8%) on the trunk, 10 (12%)
on the hands and arms, and 4 (5%) on the legs.
For the 85 histologically confirmed SCCs, we were able to
collect and analyze 72 perilesional samples. Owing to
surgical constraints for the repair method following Mohs
micrographic surgery, we were unable to obtain perilesional
tissue from 13 subjects. For the 95 controls, we obtained one
sample from a sun-exposed site on the pre-auricular area and
one from a sun-protected site on the upper inner arm.
Table 1 summarizes the characteristics of the study
population. Cases and controls were similar in age and
gender due to the frequency matching employed during
subject recruitment. Cases and controls also did not
significantly differ with regard to level of education, family
history of cancer, or history of common warts. As a group,
cases were more sun-sensitive as demonstrated by an
increased propensity to sunburn (Po0.0001) and freckle
(P¼0.007). Cases were also less likely to have ever used
tanning beds (P¼ 0.005), perhaps as a result of their
increased sun sensitivity, and more likely to have had a
history of exposure to ionizing radiation (P¼0.04). Control
subjects were more likely to have had a history of smoking
(P¼0.05) and scars from a burn injury (P¼0.03).
Table 2 shows the detection rates of HPV DNA and
adjusted odds ratios (ORs) for tissue from cases (lesional and
perilesional) and controls (sun-exposed and sun-protected).
In these analyses, the ORs are adjusted for propensity to
sunburn, as the other potential confounders, such as smoking
status, skin sensitivity, freckling, tanning bed use, burn scars,
and exposure to radiation, were not found to substantially
change the risk estimates. The data are grouped according to
the number of HPV types detected per sample, as well as by
HPV genera (alpha, beta, and gamma). The overall HPV
detection rate was similar among cases (lesional 54%;
perilesional tissue 50%), and controls (sun-exposed tissue
59%; sun-protected tissue 49%). a-Papillomavirus species 2,
3, 4, and 6, b-papillomavirus species 5, and g-papillomavirus
species 1, 2, and 4 were detected but had low prevalence
(p5% separately among both cases and controls). There was
a trend toward a higher detection rate of the a-papillomavirus
genera (mainly species 9 and 10—HPVs 6, 11, and 16)
among cases than among controls (lesions compared to sun-
exposed controls: OR¼3.0; confidence interval (CI)¼
0.6–14.3). There were similar detection rates for the genus
g-papillomavirus among lesional (8%), perilesional (6%), and
sun-exposed controls sites (7%); however, there was a
marginal decreased detection rate in sun-protected control
sites (3%). Among the b-papillomavirus, species 1 had similar
detection rates among cases and controls. However among
cases, the b-papillomavirus species 2 detection rate appeared
to differ in lesional sites (34%) as compare to perilesional
sites (17%). To explore this further, we performed conditional
logistic regression among the 72 paired specimens (lesion
versus perilesion among cases) and found that lesions
harbored significantly more b-papillomavirus species 2
DNA than perilesions (OR¼ 4.0, CI¼1.3–12.0). The paired
analyses did not show a differential detection rate within any
other species or genera (Table 2).
Some specimens harbored multiple HPV types. We
explored whether there were differential rates of detection
of multiple HPV types within the same specimen for cases
and controls, using multivariable logistic regression adjusted
for propensity for sunburn (Table 3). Tumor from cases was
more likely to have three or more HPV types detected than
sun-protected controls (OR¼6.1, 95% CI¼1.4–26.1). No
other patterns of differential detection were identified.
Table 4 examines HPV detection rates from any tissue
derived from a case (lesion or perilesion) versus any tissue
derived from a control (sun-exposed or sun-protected).
Overall, HPV detection was similar in cases (72%) and
controls (75%) (OR¼ 0.8, 95% CI¼0.3–1.8). However,
the distribution of HPV types in cases and controls was
somewhat different. There was a marginal increased risk
of infection with a-papillomavirus types (OR¼2.8,
CI¼0.8–9.8) and g-papillomavirus species 3 for cases
compared to controls (OR¼2.5, CI¼ 0.6–10.3). b-Papillo-
mavirus (including species 2) appeared to have similar
detection rates among cases compared to controls.
Lastly, we examined the risk of HPV detection and its
association with anatomic site of the tumor among cases
(data not shown). There were similar detection rates of HPV
across anatomic sites for b-papillomaviruses and g-papillo-
maviruses. However, there was a suggestion of an increased
rate of detection of b-papillomavirus species 2 in head/neck
lesions (39%) compared to other sites (19%) (OR¼ 2.7,
CI¼0.8–9.0), and there was also a decreased rate of
detection of b-papillomavirus species 1 in head/neck lesions
(23%) compared to other sites (43%) (OR¼ 0.4, CI¼ 0.1–1.2).
The a-papillomaviruses were detected in lesions on the face,
scalp, and arms and did not appear to preferentially localize
to a given anatomic site.
Several previously unreported putative HPV types were
identified in this study, including sck1, sck5, sck6, sck7, sck8,
sck17, sck25, sck27, sck29, sck30, sck46, sck4, and sck65.
Table 5 lists the partial sequences of these previously
unreported HPV types as well as previously described
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putative HPV types. Specific HPV types are allocated only
after the characterization of the respective full-length
genomes. We compiled data by lumping known HPV types
and the related partial sequences. Of note, HPV 20 was the
most frequently detected HPV type (38 overall positive
samples) and HPVs 5, 9, 15, 23, and 38 all had over 15
positive samples among the cases and controls.
DISCUSSION
Using a highly sensitive nested PCR technique, we found no
difference in overall detection of HPV DNA in tissue samples
collected from immunocompetent individuals with cuta-
neous SCC as compared to age-matched healthy controls.
However, we found that among cases, tumors were more
likely to have HPV DNA from the b-papillomavirus 2 species
than clinically normal-appearing adjacent skin. These find-
ings are supported by a recent paper by Forslund et al. (2007)
that examined 82 SCCs and obtained paired biopsy samples
from the lesion and from healthy skin from the same patient
(similar to our paired analysis). They concluded that
b-papillomavirus species 2 are associated with SCC. As we
found similar detection rates of b-papillomavirus species 2 in
our controls, we hypothesize that additional factors are
necessary for SCC development in the skin.
We found that tissue samples from cases were also
somewhat more likely to harbor HPV from the genus
a-papillomavirus (OR¼ 3.0), the same genus that includes
the high-risk types associated with cervical and anogenital
cancer (de Villiers et al., 2004), although this difference did
not reach statistical significance after controlling for the
potential confounding effect of propensity to sunburn
(CI¼0.6–14.3). Of note, the a-papillomavirus species 9,
which includes HPV type 16 implicated in cervical cancer,
was found in tissue from only two cases and was not found in
any controls, which, of the genital types, harbored only low-
risk HPV 6 and HPV 11. Among cases, a-papillomavirus HPV
detection rates were similar in tumor samples compared to
adjacent, clinically normal-appearing perilesional tissue. This
finding lends support to the theory that HPV DNA in skin
cancer is important for tumor initiation, but that additional
factors, such as p53 mutations or alterations in proapoptotic
pathways, are needed to potentiate oncogenesis.
The high prevalence of HPV DNA detected in sun-
exposed skin among our controls (59%) confirms findings
from earlier studies suggesting that HPV DNA is widely
distributed on the skin in the general population (Boxman
et al., 1997; Astori et al., 1998; Forslund et al., 1999;
Antonsson et al., 2000; Hazard et al., 2007). Studies among
immunocompetent individuals have found HPV DNA in
67–74% of plucked hairs (Boxman et al., 2000; de Koning
et al., 2007) and in 69–80% of skin swabs (Antonsson et al.,
2000; Hazard et al., 2007). Similarly, antibodies to HPV have
been detected in 53% of the sera in healthy controls (Karagas
et al., 2006). These studies, combined with our data, suggest
that HPV DNA is widespread and that occult infections can
arise on clinically normal-appearing skin.
Our HPV detection rate among SCC tumors differs
somewhat from the findings from a case–control study using
degenerate PCR primers to detect HPV in skin biopsy samples
(Iftner et al., 2003). That study detected a similar overall HPV
DNA rate in cases (60%, n¼ 72), but with a higher
prevalence (21%) of high-risk genital a-papillomavirus
genera compared to the rate in our study (8%). Further, in
contrast to our study, they rarely detected HPV in healthy
controls (4.7%, n¼106). The authors in that study suggest
that the low HPV rate in control tissue may be because the
normal skin was disinfected first, resulting in a reduction of
skin surface contamination.
Recent studies that have attempted to link seroevidence of
specific HPV types with SCC status in immunocompetent
individuals have had mixed findings. In a case–control study
looking at serum, HPV 8 seropositivity (b-papillomavirus
species 1) was positively associated with SCC status, whereas
HPV 15 seropositivity (b-papillomavirus species 2) was
negatively correlated with SCC status (Masini et al., 2003). In
a recent case–control study, HPV antibodies were more
frequently detected in SCC patients than in control subjects
(OR¼ 1.6, 95% CI¼ 1.2–2.3), especially seropositivity to
b-papillomaviruses but not a-papillomaviruses (Karagas et al.,
2006). This study was limited in that it detected seropositivity as
measured by ELISA to only a small fraction of cutaneous HPVs
(only 16 types tested) without a correlation of presence of HPV
DNA in the tissue. Our methodology involved a more sensitive
detection assay of active infection (presence of DNA, not
antibodies), and we did not detect differential rates of the genus
b-papillomavirus in our cases as compared to controls.
Table 1. Characteristics of subjects with and without
cutaneous SCC
Cases (n=85)
no./total (%)
Controls (n=95)
no./total (%) P-value
Age (mean years±SD) 72.9±12.9 70.3±9.2 0.13
Female gender 22/85 (26%) 25/95 (26%) 0.95
Family history of skin
cancer
11/65 (17%) 14/91 (15%) 0.80
Education 4high
school
39/66 (59%) 59/93 (63%) 0.58
History of warts 32/65 (49%) 56/94 (60%) 0.20
Ever smoker 38/67 (57%) 68/95 (72%) 0.05
Exposure to radiation 12/66 (18%) 7/93 (8%) 0.04
Burn scars 2/65 (3%) 12/94 (13%) 0.03
History of freckling 24/64 (38%) 17/93 (18%) 0.007
Ever used tanning beds 4/67 (6%) 21/94 (22%) 0.005
Propensity to sunburn o0.0001
Burns, blisters 8/66 (12%) 7/95 (7%)
Burns, no blisters 26/66 (39%) 12/95 (13%)
Mild burn, tans 26/66 (39%) 41/95 (43%)
No burn 6/66 (9%) 35/95 (37%)
SCC, squamous cell carcinoma.
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Tumors from cases were more likely to harbor three or
more HPV types (‘‘multiple HPVs’’) as compared to sun-
protected control skin (OR¼6.1, 95% CI¼1.4–26.1) but not
sun-exposed control skin (OR¼ 2.5, 95% CI¼ 0.8–7.9). The
profile of multiple HPV detection rates for perilesional tissue
(10%) was similar to that of sun-exposed skin in controls (8%)
(OR¼1.1). The similar rates of multiple HPVs detected in
clinically normal perilesional skin (which is often sun-
exposed, as SCCs arise mostly on sun-exposed skin) and
sun-exposed skin in controls very likely suggests that this
effect is mediated by UV light. It has previously been shown
that UV exposure in the skin induces local T-cell-mediated
immunosuppression (Hersey et al., 1983; Yoshiawa et al.,
1990; Kelly et al., 2000). Therefore, areas of the body
exposed to higher doses of UV light may be less able to fight
HPV and more likely to have multiple types detected.
Alternatively, UV may have a direct effect on viral replication
(de Villiers, 1999). We provide further support for the
interaction of UV light with HPV detection in our study by
noting a somewhat greater prevalence of HPV in sun-exposed
(59%) as compared to sun-protected skin (49%) among our
control population. Our findings are also supported by
Forslund et al. (2007) in a recently published study, which
also notes that HPV DNA was associated with sun-exposure,
both for the lesions (OR¼4.45, 95% CI¼ 2.44–8.11) and for
the healthy skin samples (OR¼ 3.65, 95% CI¼ 1.79–7.44).
The effects of UV light may have important consequences for
host resistance to HPV infection and HPV persistence. Further
studies on UV-specific DNA markers in relation to HPV status
may shed more light on this interaction.
Table 2. Rate of HPV DNA detection in subjects with and without cutaneous SCC
Cases Controls ORs (95% CI)
Genus
Lesion
(n=85) no.
(%)
Perilesion
(n=72) no.
(%)
Sun (n=95)
no. (%)
No sun
(n=95)
no. (%)
Lesion
versus
perilesion1
Lesion
versus sun2
Lesion
versus no
sun2
Perilesion
versus sun2
Perilesion
versus no
sun2
All genuses 46 (54%) 36 (50%) 56 (59%) 47 (49%) 1.2 (0.6–2.6) 0.9 (0.4–1.8) 1.2 (0.6–2.5) 0.6 (0.3–1.3) 0.9 (0.4–1.8)
a-Papillomavirus
All a-papillomavirus 7 (8%) 7 (10%) 3 (3%) 4 (4%) 0.7 (0.2–2.4) 3.0 (0.6–14.3) 1.9 (0.4–7.9) 3.4 (0.6–18.3) 2.0 (0.4–9.4)
9 2 (2%) 2 (3%) 0 (0%) 0 (0%) 1.0 (0.1–7.1) — — — —
10 3 (4%) 6 (8%) 2 (2%) 2 (2%) 0.2 (0.02–1.7) 1.6 (0.2–14.2) 0.8 (0.1–6.9) 3.2 (0.4–22.4) 1.8 (0.3–12.3)
b-Papillomavirus
All b-papillomavirus 42 (49%) 32 (44%) 51 (54%) 43 (45%) 1.3 (0.6–2.7) 1.0 (0.5–2.0) 1.3 (0.6–2.5) 0.7 (0.3–1.5) 0.9 (0.4–1.8)
1 24 (28%) 25 (35%) 29 (31%) 24 (25%) 0.7 (0.3–1.5) 1.3 (0.6–2.7) 1.3 (0.6–2.8) 1.3 (0.6–2.8) 1.3 (0.6–2.8)
2 29 (34%) 12 (17%) 28 (29%) 23 (24%) 4.0 (1.3–12.0) 1.3 (0.6–2.7) 1.7 (0.8–3.6) 0.5 (0.2–1.2) 0.6 (0.3–1.5)
3 3 (4%) 1 (1%) 6 (6%) 4 (4%) 2.0 (0.2–22.1) 1.6 (0.3–7.4) 2.7 (0.5–14.3) 0.5 (0.1–5.1) 0.9 (0.1–9.2)
g-Papillomavirus
All g-papillomavirus 7 (8%) 4 (6%) 7 (7%) 3 (3%) 1.5 (0.4–5.3) 1.0 (0.3–3.2) 2.2 (0.5–9.7) 0.6 (0.1–2.8) 1.7 (0.3–9.3)
3 3 (4%) 4 (6%) 2 (2%) 2 (2%) 0.8 (0.2–3.4) 2.1 (0.3–15.3) 1.7 (0.3–11.4) 3.0 (0.4–21.2) 2.6 (0.4–16.8)
CI, confidence interval; HPV, human papillomavirus; OR, odds ratio; SCC, squamous cell carcinoma.
1Paired analysis (n=72) comparing HPV detection in lesions to perilesion in cases.
2Adjusted for propensity to sunburn.
Table 3. Multiple HPV types detected per specimen in subjects with and without cutaneous SCC
Cases Controls Adjusted ORs (95% CI)
No. of HPV
types
Lesion (n=85)
no. (%)
Perilesion
(n=72) no. (%)
Sun (n=95)
no. (%)
No sun (n=95)
no. (%)
Lesion versus
sun
Lesion versus
no sun
Perilesion
versus sun
Perilesion
versus no sun
1 19 (22%) 17 (24%) 32 (34%) 32 (34%) 0.6 (0.2–1.3) 0.7 (0.3–1.6) 0.4 (0.2–1.2) 0.5 (0.2–1.2)
2 14 (16%) 12 (17%) 16 (17%) 12 (13%) 0.9 (0.3–2.5) 1.4 (0.5–4.1) 1.0 (0.3–2.7) 1.6 (0.5–4.5)
3+ 13 (15%) 7 (10%) 8 (8%) 3 (3%) 2.5 (0.8–7.9) 6.1 (1.4–26.1) 1.1 (0.3–4.2) 2.4 (0.5–11.7)
CI, confidence interval; HPV, human papillomavirus; OR, odds ratio; SCC, squamous cell carcinoma.
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A limitation of our study is that by setting out to detect a
broad spectrum of HPV DNA, we did not evaluate transcrip-
tional activity or assess viral load. Demonstrating active
infection can be performed using in situ hybridization to
identify replicating DNA or RNA. Purdie et al. (2005) has
previously demonstrated the feasibility of looking at trans-
cripts in SCCs by in situ hybridization but noted a low
transcriptional activity in SCCs as well as in warts, suggesting
that in situ hybridization may underestimate active HPV
infection. In our study, given the multitude of HPV species
detected, including some previously unreported types for
which there were no available clones, doing in situ
hybridization was not feasible. Similarly, we did not
determine the viral load in our samples, given the multitude
of types that were detected. Future studies need to be
performed that measure the transcriptional activity and
expression of specific viral genes as well as the viral load to
quantify HPV activity and assess its role in cutaneous
carcinogenesis.
In summary, we found that in immunocompetent hosts,
cutaneous infection with HPV is prevalent but is not a
Table 4. Paired analysis comparing HPV detection
among any tissue from a case (lesion or perilesion)
versus any tissue from a control (sun-exposed or
sun-protected skin)
Combined case
sites (n=72)
no. (%)
Combined
control sites
(n=95) no. (%) OR (95% CI)
Any HPV 52 (72%) 71 (75%) 0.8 (0.3–1.8)
a-Papillomavirus 11 (15%) 6 (6%) 2.8 (0.8–9.8)
9 4 (6%) 0 (0%) N
10 7 (10%) 3 (3%) 2.3 (0.4–12.0)
b-Papillomavirus 47 (65%) 68 (72%) 0.7 (0.3–1.6)
1 36 (50%) 39 (41%) 1.7 (0.8–3.5)
2 28 (39%) 43 (45%) 0.8 (0.4–1.6)
3 3 (4%) 10 (11%) 1.2 (0.3–4.9)
g-Papillomavirus 10 (14%) 9 (9%) 1.3 (0.5–4.0)
3 7 (10%) 4 (4%) 2.5 (0.6–10.3)
CI, confidence interval; HPV, human papillomavirus; OR, odds ratio.
Table 5. Partial sequences and related HPV types
Genus Species
Closest related
HPV type Putative HPV type No. of samples positive
b-Papillomavirus 1 5 DL231, FA23, FA65 6, 6, 1
12 FA39, X34 1, 1
19 FA14 3
20 DL284, DL287, sck1 1, 3, 1
24 vs20-4, FA18, FA127, FAIMVS11 2, 1, 2, 1
25 sck46 1
47 FA26 2
2 9 DL285, FA116 5, 1
15 sck6, DL337, FA84 3, 1, 4
17 DL436, FA40, FA114 1, 5, 7
22 sck5, RTRX10 2, 1
23 FA123, sck30, vs42-1, FA16, FA118, FAIMVS13 1, 1, 2, 8, 1, 1
38 sck27, FA51 1, 2
80 vs92-1, X14, FA85, FA108, FAIMVS14 1, 2, 1, 2, 1
3 49 sck49, sck8 1, 1
75 sck17 1
5 96 FA22, FAIMVS16, FA42 2, 1, 1
g-Papillomavirus 1 4 FA121 1
65 FA28 1
95 FA24, FA89 2, 1
2 48 FA1 1
3 50 sck7, sck25, sck29, FA4, FA8, FA46, FA55, FA81, FAIMVS5 1, 3, 1, 1, 1, 1, 1, 1, 2
4 60 sck65 1
HPV, human papillomavirus.
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necessary factor for SCC development. Similar rates of HPV
were detected in tissue samples from cases as compared to
controls. However, among cases, tumors were more likely to
have HPV DNA isolated from b-papillomavirus species 2
than adjacent healthy tissue (paired analysis, OR¼4.0,
CI¼1.3–12.0). The high prevalence of HPV DNA detected
among controls suggests that HPV DNA is widely distributed
among the general population. However, the differential
detection of HPV b-papillomavirus species in tumors among
cases suggests that certain HPV types may be involved in the
progression of cutaneous SCCs. There may be an interaction
with HPV and UV light, either through the induction of
oncogenes such as p53 or through the inactivation of tumor
suppressor genes such as Rb that can potentiate carcinogen-
esis. Given the widespread occurrence of HPV, future studies
need to be performed that measure the expression of certain
viral genes so that the activity of HPV can be quantified.
Likewise, information on type-specific humoral immune
response activities over time could help elucidate the
interaction of these viral proteins with host cell functions.
MATERIALS AND METHODS
Subject eligibility and enrollment
Inclusion and exclusion criteria. Caucasian men and women
over the age of 55 years who were not immunosuppressed (owing to
organ transplantation or immunosuppressive therapy for cancer)
were eligible. Subjects were excluded if they had a history of genetic
syndromes that would increase susceptibility to damage from UV
exposure, including xeroderma pigmentosum, nevoid basal cell
syndrome, albinism, epidermodysplasia verruciformis, epidermolysis
bullosa dystrophica, dyskeratosis congenital, and psoralen with UV
light treatment. Digit and mucosal lip lesions were also excluded. All
subjects provided informed consent according to procedures
approved by the Institutional Review Boards of the University of
Washington and other participating institutions. The study was
conducted according to the Declaration of Helsinki Principles.
Subject recruitment. Cases (N¼ 132) were recruited from patients
with a histologically confirmed cutaneous SCC (lip, finger, and
genital tumors were excluded) who were undergoing surgical
resection of their SCC at dermatology clinics at the University of
Washington Medical Center, the VA Puget Sound Health Care
System, Group Health Cooperative, and a private medical practice.
Controls (N¼ 95) were individuals without a prior history of skin
cancer who were recruited by a letter sent from their primary care
providers and were matched to the cases by age±5 years.
Data collection
Interview procedures. A standardized interview was administered
to all study subjects to collect information pertaining to the following
potential confounding variables: (i) demographic or behavioral
information, including age, sex, ethnicity, income, and exposure to
tobacco smoke, arsenic, hydrocarbons, or radiation; (ii) physical
characteristics such as propensity to sunburn and freckle; (iii) history
of pertinent dermatological conditions, including actinic keratosis,
burn scars, ulcers, and warts; and (iv) lifetime history of sun
exposure, including a history of tanning bed use, and number of
blistering sunburns.
Physical examination. All control subjects had a full skin
examination of their face, neck, scalp, ears, back, torso, buttocks,
arms, and legs performed by a dermatologist (MMA) to insure
absence of lesions suspicious for skin cancer. If suspicious lesions
were identified, the subject was deemed ineligible and an
appropriate medical referral was initiated.
Collection of skin specimens. Cases: A small portion of the
residual SCC as well as adjacent clinically uninvolved perilesional
skin (Figure 2) was collected from each subject and divided into
thirds. One third was placed in 10% neutral buffered formalin for
histopathologic confirmation of SCC at the time of the surgery
(hematoxylin and eosin stain), another third placed into standard
viral transport media, and the final portion placed into ethanol.
Controls: For each subject, punch biopsies of clinically normal
skin were obtained from a sun-exposed (pre-auricular) site as well as
from a sun-protected site from the upper inner arm. After intradermal
anesthesia with 1ml of 1% lidocaine with epinephrine at 1:100,000,
a 4-mm punch biopsy was inserted to the level of the subcutaneous
fat. Each specimen was divided into thirds. One third was placed in
10% neutral buffered formalin for histopathologic evaluation
(hematoxylin and eosin stain), another third placed into standard
viral transport media for HPV PCR-detection assays, and the final
portion placed into ethanol for future analyses. The defect was
closed with two simple interrupted 5-0 fast-absorbing gut sutures.
Laboratory methods
Histopathology methods. Routine paraffin-embedded tissue was
prepared from the biopsy specimens and then sectioned and stained
with hematoxylin and eosin to confirm the diagnosis.
HPV detection. DNA from the biopsies was extracted with buffer-
saturated phenol–chloroform–isoamyl alcohol and subsequently
precipitated with ethanol. Three different PCR protocols were used
to amplify HPV DNA (Snijders et al., 1991; Berkhout et al., 1995;
Forslund et al., 1999). The first protocol used primers originally
designed for detection of epidermodysplasia verruciformis and
epidermodysplasia verruciformis-related cutaneous HPV types, but
by modifying the amplification conditions, almost all known HPV
types were amplified (de Villiers, 1997). The second protocol
allowed for detection of mucosal HPVs (Snijders et al., 1991) and the
Perilesion
Lesion
Figure 2. SCC of the ear demonstrating lesional and perilesional tissue.
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third is designed to detect all known cutaneous HPV types (Forslund
et al., 1999).
Protocol 1: DNA (100 ng per 50 ml reaction volume per sample)
was denatured at 94 1C for 9minutes and then immediately followed
by 40-cycle amplification in the Thermal Cycler (Perkin Elmer Cetus,
Norwalk, CT). Each cycle consisted of denaturation (94 1C for
1minute), annealing (50 1C for 2minutes), and extension (72 1C for
1minute), with a final extension at 72 1C for 5minutes in the last
cycle followed by cooling down to 4 1C. The reaction mixture
contained 1mM dNTP, 50pmol of each primer, 1.25U Ampli Taq
Gold (Perkin Elmer), and supplied buffer with 2.5mM of MgCl2. An
aliquot of 2–3ml PCR product was used for the subsequent nested
PCR amplification, using the same conditions as described above.
Aliquots of the first, as well as the nested amplification products,
were separated on a 1.5% agarose gel. If visible bands were of
expected sizes (first 460 bp, nested 380 bp) in both reaction
products, both products were eluted from the gel for further analysis.
Protocol 2: DNA (100 ng per 50 ml reaction volume per sample)
was amplified with a pair of primers GP5þ and GP6þ , which
generated HPV fragments of 140–150 bp. Amplification was
completed through 40 cycles (94 1C for 1minute, annealing at
40 1C for 2minutes, and extension at 72 1C for 1.5minutes), with an
initial heating for 9minutes at 94 1C and an end extension for
4minutes at 72 1C. The reaction mixture contained 1mM dNTP,
50 pmol of each primer, 1.25U Ampli Taq Gold (Perkin Elmer), and
supplied buffer with 2.5mM of MgCl2.
Protocol 3: DNA (100 ng per 50ml reaction volume per sample)
was amplified using the FAP59 and FAP64 primers. Amplicons of
480 pb were generated. Amplification was performed after an initial
heating for 8minutes at 94 1C followed by 45 cycles each of
1.5minutes at 94 1C for denaturation, 1.5minutes at 50 1C for
annealing, and 1.5minutes at 72 1C for extension. The reaction was
completed with a final extension cycle of 5minutes at 72 1C. The
reaction mixture contained 200mM of dNTPs and 50 pmol of each
primer, and MgCl2 was added to a final concentration of 3.5mM.
Analysis of amplified products generated by the three
protocols. An aliquot of amplified products for each sample was
subjected to 1.5 or 2% agarose gel electrophoresis and visualized
after EtBr staining. If only one band of the expected size was visible,
the rest of the PCR products from that sample were purified directly
using High Pure PC Product Purification kit (Roche, Roche Applied
Science, Indianapolis, IN). If more than one band was visible, the
rest of the PCR products from that sample were separated on another
agarose gel. The excised gel segments containing the expected bands
were purified using the Genomed-Gel extraction Spinkit (Genomed,
St Louis, MO). The resulting products were cloned into a plasmid
vector using either TA Cloning Kit (Invitrogen, Carlsbad, CA) or the
TOPO-TA-Cloning Kit (Invitrogen). All ligations were performed
overnight at 14 1C. Clones containing target inserts were identified
by restriction enzyme digestion and analyzed by gel electrophoresis.
Up to 10 clones per sample were subjected to sequencing.
Sequencing was performed by an ABI Model Sequences using Big
Dye terminator chemistry (Perkin Elmer Applied Biosystems Divi-
sion, Waltham, MA). The sequences were compared to the DNA
sequences of all known HPV types in the European Molecular
Biology Laboratory database (European Bioinformatics Institute,
Cambridge, UK) and GenBank (National Center for Biotechnology
Information, NIH, Bethesda, MD). An HPV type was defined by less
than 90% homology within the L1 open reading frame to any other
known type. The putative, previously unreported HPV types were
sequenced in full on both DNA strands for complete identification.
Statistical methods. Differences between cases and controls were
assessed using w2 analyses to compare categorical variables and
Student’s t-test to compare continuous measures. The risk of SCC
associated with HPV was estimated using multivariable logistic
regression, adjusting for propensity to sunburn. Conditional logistic
regression was also used to assess the risk of SCC among paired
specimens (lesional versus perilesional within cases). A two-sided
0.05 level test determined statistical significance for all analyses. All
analyses were conducted using SAS 9.1 (SAS Institute Inc., Cary, NC).
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